RATIONALE: This study investigated the acute mood effects of oral MDMA, methamphetamine, and placebo in a double-blind laboratory study. METHODS:Fifty-two healthy participants comprised abstinent recreational users of stimulant drugs, 27 female and 25 male, mean age 24.8 years. Three test sessions involved acute 100 mg oral 3.4-methylendioxymethamphetamine (MDMA), 0.42 mg/kg oral methamphetamine, and matching placebo. Drug administration was counterbalanced, testing was double-blind, and medical supervision was present throughout. Car-driving performance on a laboratory simulator was assessed after 3 and 24 h, with the findings being presented elsewhere. Positive and negative moods (PANAS self-ratings) were completed before drug administration, 3, 4.5, and 24 h later. Blood samples were taken to monitor drug plasma levels. RESULTS: Following MDMA, there were no significant increases in positive moods, whereas negative moods were significantly higher than under placebo. Methamphetamine led to significant increases in both positive and negative moods. The MDMA findings contrast with the elated moods, typically noted by dance clubbers on Ecstasy. However, they are consistent with some previous laboratory findings, since a wide array of positive and negative mood changes have been demonstrated. One possible explanatory factor was the neutral environmental situation, particularly if a primary action of MDMA is to intensify ongoing psychological states. Other explanatory factors, such as dosage, gender, post-drug timing, neurohormonal aspects, and social factors, are also discussed. CONCLUSIONS: In the laboratory, acute methamphetamine led to significantly higher positive moods. However, against expectations, MDMA did not generate a significant increase in positive moods.
RCT Entities:
RATIONALE: This study investigated the acute mood effects of oral MDMA, methamphetamine, and placebo in a double-blind laboratory study. METHODS: Fifty-two healthy participants comprised abstinent recreational users of stimulant drugs, 27 female and 25 male, mean age 24.8 years. Three test sessions involved acute 100 mg oral 3.4-methylendioxymethamphetamine (MDMA), 0.42 mg/kg oral methamphetamine, and matching placebo. Drug administration was counterbalanced, testing was double-blind, and medical supervision was present throughout. Car-driving performance on a laboratory simulator was assessed after 3 and 24 h, with the findings being presented elsewhere. Positive and negative moods (PANAS self-ratings) were completed before drug administration, 3, 4.5, and 24 h later. Blood samples were taken to monitor drug plasma levels. RESULTS: Following MDMA, there were no significant increases in positive moods, whereas negative moods were significantly higher than under placebo. Methamphetamine led to significant increases in both positive and negative moods. The MDMA findings contrast with the elated moods, typically noted by dance clubbers on Ecstasy. However, they are consistent with some previous laboratory findings, since a wide array of positive and negative mood changes have been demonstrated. One possible explanatory factor was the neutral environmental situation, particularly if a primary action of MDMA is to intensify ongoing psychological states. Other explanatory factors, such as dosage, gender, post-drug timing, neurohormonal aspects, and social factors, are also discussed. CONCLUSIONS: In the laboratory, acute methamphetamine led to significantly higher positive moods. However, against expectations, MDMA did not generate a significant increase in positive moods.
Authors: G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes Journal: Soc Neurosci Date: 2009 Impact factor: 2.083
Authors: M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí Journal: Psychopharmacology (Berl) Date: 2004-04-08 Impact factor: 4.530
Authors: Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis Journal: J Clin Psychopharmacol Date: 2008-08 Impact factor: 3.153
Authors: Rui Tao; Ibrahim M Shokry; John J Callanan; H Daniel Adams; Zhiyuan Ma Journal: Psychopharmacology (Berl) Date: 2014-10-11 Impact factor: 4.530
Authors: Nam Jun Kim; Yeonhee Ryu; Bong Hyo Lee; Suchan Chang; Yu Fan; Young S Gwak; Chae Ha Yang; Kyle B Bills; Scott C Steffensen; Jin Suk Koo; Eun Young Jang; Hee Young Kim Journal: Addict Biol Date: 2018-01-23 Impact factor: 4.280
Authors: Patrick Recinto; Anjali Rose H Samant; Gustavo Chavez; Airee Kim; Clara J Yuan; Matthew Soleiman; Yanabel Grant; Scott Edwards; Sunmee Wee; George F Koob; Olivier George; Chitra D Mandyam Journal: Neuropsychopharmacology Date: 2011-12-28 Impact factor: 7.853
Authors: Con Stough; Rebecca King; Katherine Papafotiou; Phillip Swann; Edward Ogden; Keith Wesnes; Luke A Downey Journal: Psychopharmacology (Berl) Date: 2011-10-22 Impact factor: 4.530
Authors: John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer Journal: J Psychopharmacol Date: 2013-12-10 Impact factor: 4.153
Authors: Jessica Ruiz-Medina; Ana Pinto-Xavier; Marta Rodríguez-Arias; José Miñarro; Olga Valverde Journal: Psychopharmacology (Berl) Date: 2012-11-29 Impact factor: 4.530